Pom down under
Top 20
Last edited:
BRN Operational Losses And Other Financial Factors Since 2019
- Thread starter Dave Evans
- Start date
Dave Evans
Regular
BRN’s December Quarterly out today 
R&D, marketing and administration costs for 2024 were $15.8million. When the share based expenses come out in next month’s Annual Report it will fully reveal BRN’s operational losses for 2024.
A few takeaways from this and other recent BRN Quarterly Reports show the Capital Raise in July - August 2024 raised $25million but by the time the September Quarterly came out it showed that was all BRN had left in cash.
The September Quarterly also showed BRN had 7.7 Quarters of funding available but the latest (December) Quarterly shows BRN only has 5.1 Quarters of funding.
Some of that heavily diluting CR in July - August 24 went towards payments to LDA Capital to fulfill obligations under its Put Option Agreement. And then this month BRN amended the LDA arrangement (for the fourth time) increasing it to $140million and further diluting shares. Of that $140million, $68million has already been used.
R&D, marketing and administration costs for 2024 were $15.8million. When the share based expenses come out in next month’s Annual Report it will fully reveal BRN’s operational losses for 2024.
A few takeaways from this and other recent BRN Quarterly Reports show the Capital Raise in July - August 2024 raised $25million but by the time the September Quarterly came out it showed that was all BRN had left in cash.
The September Quarterly also showed BRN had 7.7 Quarters of funding available but the latest (December) Quarterly shows BRN only has 5.1 Quarters of funding.
Some of that heavily diluting CR in July - August 24 went towards payments to LDA Capital to fulfill obligations under its Put Option Agreement. And then this month BRN amended the LDA arrangement (for the fourth time) increasing it to $140million and further diluting shares. Of that $140million, $68million has already been used.
Pom down under
Top 20
BRN’s December Quarterly out today
R&D, marketing and administration costs for 2024 were $15.8million. When the share based expenses come out in next month’s Annual Report it will fully reveal BRN’s operational losses for 2024.
A few takeaways from this and other recent BRN Quarterly Reports show the Capital Raise in July - August 2024 raised $25million but by the time the September Quarterly came out it showed that was all BRN had left in cash.
The September Quarterly also showed BRN had 7.7 Quarters of funding available but the latest (December) Quarterly shows BRN only has 5.1 Quarters of funding.
Some of that heavily diluting CR in July - August 24 went towards payments to LDA Capital to fulfill obligations under its Put Option Agreement. And then this month BRN amended the LDA arrangement (for the fourth time) increasing it to $140million and further diluting shares. Of that $140million, $68million has already been used.
AusEire
Founding Member. It's ok to say No to Dot Joining
So in essence what your saying is, is that Brainchip have in excess of $95million in funding available to them by means of $25m in cash and $72m remaining in potential funding from LDA IF they want to call on it.BRN’s December Quarterly out today
R&D, marketing and administration costs for 2024 were $15.8million. When the share based expenses come out in next month’s Annual Report it will fully reveal BRN’s operational losses for 2024.
A few takeaways from this and other recent BRN Quarterly Reports show the Capital Raise in July - August 2024 raised $25million but by the time the September Quarterly came out it showed that was all BRN had left in cash.
The September Quarterly also showed BRN had 7.7 Quarters of funding available but the latest (December) Quarterly shows BRN only has 5.1 Quarters of funding.
Some of that heavily diluting CR in July - August 24 went towards payments to LDA Capital to fulfill obligations under its Put Option Agreement. And then this month BRN amended the LDA arrangement (for the fourth time) increasing it to $140million and further diluting shares. Of that $140million, $68million has already been used.
Dave Evans
Regular
If you think BRN has $25million in cash left then you didn’t read my post (or the Quarterly Report) correctly. BRN has had operational losses of over $100million over the last five years and 2024 was another year of losses.
The capital raises and LDA arrangement being increased continues to dilute shares and the Frontgrade and Airforce deals only generate a small amount of capital so in spite of all the hype there is very little supporting revenue.
Last edited:
Space Cadet
Regular
Dave Evans
Regular
BRN isn’t a pre revenue company, all companies have revenue. The problem is the losses in their revenue is in the millions, and many times greater than the income.
A lot of chippers here focus on hype and often refer to BRN’s institutional investors and they also talk about charts, shorter’s and how the SP is being manipulated. In my experience it’s the big investment banks and institutional investors that manipulate stocks the most, that’s one way they make their profits.
Of all the institutional investors, I lost count of the number of times I saw UBS downgrade a company, then scoop up shares, only to be followed by putting out a good report on the company, then selling and then as they say, rinse and repeat. Through another company I own, I saw illegal money funnelled out of Africa to UBS, they are the one institution I am most sus on above all others.
I started looking at charts over 10 years ago, then hype, forecasts, supply and demand, macro economics, institutional investors manipulating stocks etc. When I see the changes in the buy and sell orders of BRN shares it looks like there is a lot of manipulation to me.
In the end, when companies keep running at losses and having to keep raising more capital I go back to the fundamentals ie The financials.
A lot of chippers here focus on hype and often refer to BRN’s institutional investors and they also talk about charts, shorter’s and how the SP is being manipulated. In my experience it’s the big investment banks and institutional investors that manipulate stocks the most, that’s one way they make their profits.
Of all the institutional investors, I lost count of the number of times I saw UBS downgrade a company, then scoop up shares, only to be followed by putting out a good report on the company, then selling and then as they say, rinse and repeat. Through another company I own, I saw illegal money funnelled out of Africa to UBS, they are the one institution I am most sus on above all others.
I started looking at charts over 10 years ago, then hype, forecasts, supply and demand, macro economics, institutional investors manipulating stocks etc. When I see the changes in the buy and sell orders of BRN shares it looks like there is a lot of manipulation to me.
In the end, when companies keep running at losses and having to keep raising more capital I go back to the fundamentals ie The financials.
Last edited:
Dave Evans
Regular
Seems a lot of shareholders are wanting to know if there’s any changes among the T20 shareholders. Shouldn’t have long to wait as its generally shown in the last pages of the Annual Report later this month. What I’ll be looking for in the Annual Report is how much the share based expenses contribute to the operational losses
Pom down under
Top 20
We don’t give a
what you’ll be looking for because us shareholders want $$$$ and $$$$ only.
rgupta
Regular
Frankly speaking all those losses are nothing compared to money poured in by big players like intel, ibm on SNNs and even to your disbelief a lot of companies may had spend more on evaluating our technology.
Matter of fact is a new technology may need billions of dollars before a success.
To me the only reason team brainchip is trying the same at such low budgets is, they are very small in size but still progressing.
New technology is no less than a big biotech innovations, which take billions of dollars and years of trialing before becoming main stream. The only difference is in bio tech their is a set path where they can prove the efficacy but in tech market behaviour is much different.
End of the day just think this way if our technology is successful we can be as big as ARM and if not then we can keep on struggling for years just like MRAM.
If you are afraid of burning money then better to invest in established technologies than start ups.
Dyor
Dave Evans
Regular
I learned early on here just to to stick to the BRN’s financials rather than give opinions but if you want to know what I think I’ll tell you.
I don’t know why shareholders compare BRN to the big players. BRN and its shareholders have hyped its technology more than any other company I’ve had shares in. They’ve had companies try their tech (like Mercedes) but not commit to incorporating it, and more recently the hype is around aerospace, defence and now shareholders are even hyping a BRN chip in Nintendo’s latest console. I don’t know whether people actually believe Nintendo would commit paying 10% royalties to another company simply for what BRN would bring.
So many partnerships but none bringing in enough cash to make even a slight dent in the losses. BRN promoted its tech as being years ahead but the years have rolled on and no cash in spite of multiple partnerships and multiple uses.
China and the US defence have enough resources to develop and create their own versions of BRN’s tech and I can’t see the US paying to use BRN’s IP. All I see coming In upcoming Annual Report are the same old partnerships being rehashed like they have been over and over.
I’m sorry I didn’t sell when it hit $0.50 and I’m also sorry I didn’t sell recently at $0.40 but not as sorry I didn’t sell when it was $2. I just got sucked in by the hype. Now I have money in the bank from other shares I can hold or sell, it doesn’t make any difference to me at this point in time but I’ll still keep an eye on, and post the financials.
If nothing else, what I keep seeing is it’s a trading stock that is being manipulated by institutional investors, but that’s just my opinion and I won’t waste my time on more opinions, just revenues.
As far as stocks, I might look at selling if I see a high dividend paying stock looking like like it’s going to beat its forecasts
Pom down under
Top 20
Dave Evans
Regular
Anyone genuinely thinking the SP will hit $0.40c anytime soon could buy around 5million shares on offer today for $0.33.
5million is an interesting number, I imagine it’s about half the amount of dollars BRN will be adding to its losses through share based expenses in 2024, which would take overall operational losses to between $25mil and $30mil for a second straight year.
5million is an interesting number, I imagine it’s about half the amount of dollars BRN will be adding to its losses through share based expenses in 2024, which would take overall operational losses to between $25mil and $30mil for a second straight year.
rgupta
Regular
I love your assessment and only one suggestion.
Brainchip does not suit your taste at this point may be come back later.
Dyor
Dave Evans
Regular
There’s a lot of the usual hype leading up to the Annual Report. It seems like a continuation of the speculation of the last 6 years. The same 6 years of increasing operational losses and capital raises, the proof being in BRN’s Announcements over that same period.
Every year of announcements nearly a mirror image of the year before. Like last year’s CES, and ahead of this year’s CES in January there was speculation about potential announcements and deals that didn’t eventuate. Speculation about Nintendo Switch, partnerships and applications, LinkedIn posts, podcasts, announcements about aerospace and defence, and now glasses for predicting epileptic seizures.
Ahead of the Annual Report due this week, I even read comments where shareholders were down playing revenues and annual losses that are approaching $30million. Companies form, and others invest in them to make money, not lose it, and revenues and losses are accurate and essential ways of assessing a company’s progress.
Recently BRN announced another amendment to the LDA Capital POA providing operational cash, but $68million of that was already used up. Previously companies that LDA Capital has provided POA’s to have gone into voluntary administration so this method of raising capital doesn’t remove the risk associated with funding, but it does lead to shareholder dilution.
I imagine the Annual Report will focus on the Frontgrade and AFRL contracts, the usual other partnerships, BRN’s IP Akida and TENN’s technology and the recent announcement of the Onsor glasses while trying not to draw attention to the financial losses and lack of revenue using the IP based financial strategy.
As far as red flags go, its generally considered a red flag when someone who has as much insight into a company as Anil Mankar has, sells around 30million shares (around 25million of those being sold at the December high before the decline) and not necessarily a good look when it’s announced after the market closed for the day.
That followed a day where the share price rose following the Onsor announcement. A look at Onsor will show you that they also have very low revenue and though the announcement talks up the potential of their glasses, like with every other partnership BRN has, there are no signs of any income substantial enough to offset the millions in losses.
As far as applications that forewarn against seizures, there are numerous wearable devices that perform this function, two of which are approved by the FDA and EU. They are a smart watch and an adhesive patch fixed to the subject’s bicep. I imagine these would be more suitable for wearing at night as seizures also occur during sleep.
Something shareholders might not have considered is, Trump recently said he wanted to cut defence spending and knowing the way he operates, I imagine if the US found BRN’s tech useful, rather than paying royalties, Trump might pressure his connections in the tech sector to stall and stifle BRN’s progress until he got BRN down to a point they could attempt to pull off a sub $0.20 takeover. BRN also states it’s risks include breaches of its technology and the risks associated with the costs of litigation.
They’re just a few things to consider when the Annual Report comes out, and so is the chart below showing BRN’s share price movements over the last year. You don’t be a chartist to see the similarity between now and this time last year
Every year of announcements nearly a mirror image of the year before. Like last year’s CES, and ahead of this year’s CES in January there was speculation about potential announcements and deals that didn’t eventuate. Speculation about Nintendo Switch, partnerships and applications, LinkedIn posts, podcasts, announcements about aerospace and defence, and now glasses for predicting epileptic seizures.
Ahead of the Annual Report due this week, I even read comments where shareholders were down playing revenues and annual losses that are approaching $30million. Companies form, and others invest in them to make money, not lose it, and revenues and losses are accurate and essential ways of assessing a company’s progress.
Recently BRN announced another amendment to the LDA Capital POA providing operational cash, but $68million of that was already used up. Previously companies that LDA Capital has provided POA’s to have gone into voluntary administration so this method of raising capital doesn’t remove the risk associated with funding, but it does lead to shareholder dilution.
I imagine the Annual Report will focus on the Frontgrade and AFRL contracts, the usual other partnerships, BRN’s IP Akida and TENN’s technology and the recent announcement of the Onsor glasses while trying not to draw attention to the financial losses and lack of revenue using the IP based financial strategy.
As far as red flags go, its generally considered a red flag when someone who has as much insight into a company as Anil Mankar has, sells around 30million shares (around 25million of those being sold at the December high before the decline) and not necessarily a good look when it’s announced after the market closed for the day.
That followed a day where the share price rose following the Onsor announcement. A look at Onsor will show you that they also have very low revenue and though the announcement talks up the potential of their glasses, like with every other partnership BRN has, there are no signs of any income substantial enough to offset the millions in losses.
As far as applications that forewarn against seizures, there are numerous wearable devices that perform this function, two of which are approved by the FDA and EU. They are a smart watch and an adhesive patch fixed to the subject’s bicep. I imagine these would be more suitable for wearing at night as seizures also occur during sleep.
Something shareholders might not have considered is, Trump recently said he wanted to cut defence spending and knowing the way he operates, I imagine if the US found BRN’s tech useful, rather than paying royalties, Trump might pressure his connections in the tech sector to stall and stifle BRN’s progress until he got BRN down to a point they could attempt to pull off a sub $0.20 takeover. BRN also states it’s risks include breaches of its technology and the risks associated with the costs of litigation.
They’re just a few things to consider when the Annual Report comes out, and so is the chart below showing BRN’s share price movements over the last year. You don’t be a chartist to see the similarity between now and this time last year
Last edited:
Pom down under
Top 20
I can’t see any similarities between now and last year and the only difference I can see is that company has progressed so much in the last 12 months and will continue to do so in the next 12 months as well.
Dave Evans
Regular
It seems the BOD had done everything they can to keep the share price up ahead of the Annual Report, possibly because the share based expenses on top of millions in other operating losses are again going to take their toll on revenue, and no doubt it won’t be long before we see another announcement regarding unquoted securities.
It also doesn’t bode well when a top 4 substantial shareholder sells down 25million shares and BRN holds off announcing it for two months. This morning Morningstar downgraded BRN to $0.22
It also doesn’t bode well when a top 4 substantial shareholder sells down 25million shares and BRN holds off announcing it for two months. This morning Morningstar downgraded BRN to $0.22
Pom down under
Top 20
That’s up from 0.15c the other day
Similar threads
